Compare Summit Therapeutics Inc (SMMT) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs BlackRock TCP Capital Corp — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while BlackRock TCP Capital Corp trades at $3.24 (market cap $270.17M). The key difference: Summit Therapeutics Inc is far larger — about 38.8× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 26.09% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TCPC | |
|---|---|---|
Market Cap | $10.48B | $270.17M |
Sector | Health | Financials |
52-Week High | $29.32 | $7.64 |
52-Week Low | $13.05 | $3.14 |
Enterprise Value | $9.90B | — |
Dividend Yield | — | 26.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
TCPC trades at $3.21, down 3.02% today, with a bearish technical signal from moving averages. The company reported negative revenue and net losses in 2025, though it beat Q1 2026 EPS estimates. A dividend of $0.17 per share is scheduled for June 30, 2026. Analyst consensus is mixed, with 31% buy ratings but 54% hold, reflecting caution amid financial challenges and an ongoing legal investigation into fiduciary duties.
The outlook remains cautious due to persistent negative earnings and revenue trends, with profitability metrics like ROE at -18.74% indicating weak shareholder returns. Risks include the shareholder lawsuit and competitive pressures in the BDC sector. Near-term focus is on the Q2 2026 earnings report due August 6, 2026, which could influence sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
